110,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
55 °P sammeln
  • Broschiertes Buch

An up-to-date comprehensive overview of the GABA B receptor system with a particular focus on the most recent therapeutic applications and potential. This receptor system has recently been implicated in several diseases and disorders including gastroesophageal reflux disease, epilepsy, mood disorders, depression, and alcohol and substance use disorder. The authors, leading researchers in the field, explore a number of approaches, including medicinal chemistry, molecular biology, physiology, and preclinical and clinical pharmacology. This overview provides a translational perspective on the potential of the GABA B receptor pharmacology. …mehr

Produktbeschreibung
An up-to-date comprehensive overview of the GABA B receptor system with a particular focus on the most recent therapeutic applications and potential. This receptor system has recently been implicated in several diseases and disorders including gastroesophageal reflux disease, epilepsy, mood disorders, depression, and alcohol and substance use disorder. The authors, leading researchers in the field, explore a number of approaches, including medicinal chemistry, molecular biology, physiology, and preclinical and clinical pharmacology. This overview provides a translational perspective on the potential of the GABA B receptor pharmacology.
Autorenporträt
Giancarlo Colombo is a researcher at the Neuroscience Institute, Section of Cagliari, National Research Council of Italy. He has previously worked at the Laboratory of Physiologic and Pharmacologic Studies, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA, and the Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC, USA. His research interest is primarily on neurobiology and pharmacology of alcohol use disorder, with focus on the role of GABAB receptor in the control of multiple alcohol-related behaviors and the development of GABAB receptor ligands as possible pharmacotherapies for alcohol use disorder. He has published approximately 200 papers in peer-reviewed journals and about 20 book chapters. He serves on the editorial board of the journals Alcohol and Alcohol and Alcoholism.